Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction

• Published in: The American heart journal Vol. 143; no. 6; pp. 1092 - 1100
• Main Authors: Jeejeebhoy, Farida, Keith, Mary, Freeman, Michael, Barr, Aiala, McCall, Michele, Kurian, Regina, Mazer, David, Errett, Lee
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.06.2002; Elsevier; Elsevier Limited
• Subjects: Aged; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular disease; Carnitine - administration & dosage; Carnitine - analysis; Carnitine - metabolism; Coenzymes; Dietary Supplements; Double-Blind Method; Drug therapy; Female; Heart; Heart attacks; Heart failure; Heart Failure - metabolism; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Heart surgery; Humans; Male; Malnutrition; Medical sciences; Middle Aged; Mortality; Myocardium - metabolism; Proteins; Radionuclide Ventriculography - methods; Taurine - administration & dosage; Taurine - analysis; Taurine - metabolism; Ubiquinone - administration & dosage; Ubiquinone - analogs & derivatives; Ubiquinone - analysis; Ubiquinone - metabolism; Ventricular Dysfunction, Left - metabolism; Ventricular Dysfunction, Left - therapy; Human; Heart failure; Taurine; Prognosis; Cardiovascular disease; Supplemented diet; Left ventricle; Carnitine; Diet therapy; Ubiquinone; Dysfunction; Heart disease; Aminoacid
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1067/mhj.2002.121927

Background Congestive heart failure depletes the myocardium of carnitine, coenzyme Q10 (CoQ10), and taurine—substances known to influence mitochondrial function and cell calcium. We hypothesized that feeding patients a nutritional supplement that contained carnitine, CoQ10, and taurine would result in higher myocardial levels of these nutrients and improve left ventricular function. Methods Forty-one patients who underwent aortocoronary artery bypass with an ejection fraction ≤40% at referral were randomly assigned to a double-blind trial of supplement or placebo. Radionuclide ventriculography was performed at randomization and before surgery. Surgical myocardial biopsies, adjusted for protein content, were analyzed for carnitine, CoQ10, and taurine levels. Results The groups were well matched. Minor exceptions were supplement group versus placebo group for digoxin use (7 vs 0, respectively; P =.009) and age (62 ± 11 years vs 69 ± 5 years, respectively; P =.04). There were significantly higher levels in the treated group compared with the placebo group for myocardial levels of CoQ10 (138.17 ± 39.87 nmol/g wet weight and 56.67 ± 23.08 nmol/g wet weight; P =.0006), taurine (13.12 ± 4.00 μmol/g wet weight and 7.91 ± 2.81 μmol/g wet weight; P =.003), and carnitine (1735.4 ± 798.5 nmol/g wet weight and 1237.6 ± 343.1 nmol/g wet weight; P =.06). The left ventricular end-diastolic volume fell by −7.5 ± 21.7 mL in the supplement group and increased by 10.0 ± 19.8 mL in the placebo group (P =.037). Conclusions Supplementation results in higher myocardial CoQ10, taurine, and carnitine levels and is associated with a reduction in left ventricular end-diastolic volume in patients with left ventricular dysfunction before revascularization. Because the risk of death for surgical revascularization is related to preoperative left ventricular end-diastolic volume, supplementation could improve outcomes. (Am Heart J 2002;143:1092-100.)